What's Going On With Longevity Health Shares Monday?

Longevity Health Holdings, Inc. (NASDAQ:XAGE shares are soaring on Monday after the company announced it entered into a merger agreement with 20/20 BioLabs, Inc., a provider of testing for the early detection and management of chronic disease.

The Details: The deal, which follows Longevity's January acquisition of Elevai Skincare, aligns with the company's strategy to expand into diagnostics to build synergies with its existing bio-aesthetics portfolio, as well as its contemplated expansion into nutrition.

20/20 BioLabs offers OneTest, a multi-cancer early detection blood test, and is preparing to launch a new “longevity test” that analyzes biomarkers tied to aging and chronic disease. The combined company anticipates over $1 million in operational savings and potential cross-selling across both customer bases.

The merger is expected to double Longevity’s fiscal-year 2025 anticipated revenue from approximately $3-4 million to approximately $7-8 million.

The merger is expected to close in the third quarter of 2025, subject to shareholder approval and other customary closing conditions.

See Also: Crude Oil Moves Lower; M&T Bank Earnings Miss Views

XAGE Price Action: At the time of publication, Longevity shares are trading 51.7% higher at 19 cents, according to data from Benzinga Pro.

Image: via Shutterstock